company background image
SGTX logo

Sigilon Therapeutics NasdaqGS:SGTX Stock Report

Last Price

US$22.47

Market Cap

US$56.5m

7D

-2.3%

1Y

150.5%

Updated

15 Aug, 2023

Data

Company Financials +

Sigilon Therapeutics, Inc.

NasdaqGS:SGTX Stock Report

Market Cap: US$56.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SGTX Stock Overview

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases.

SGTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Sigilon Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sigilon Therapeutics
Historical stock prices
Current Share PriceUS$22.47
52 Week HighUS$28.00
52 Week LowUS$3.77
Beta4.11
1 Month Change5.74%
3 Month Change253.47%
1 Year Change150.50%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.03%

Recent News & Updates

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Apr 17
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Recent updates

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Apr 17
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Aug 04

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Jun 14

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Mar 04
What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.

Dec 17

Shareholder Returns

SGTXUS BiotechsUS Market
7D-2.3%-0.06%2.1%
1Y150.5%9.8%30.4%

Return vs Industry: SGTX exceeded the US Biotechs industry which returned 0.6% over the past year.

Return vs Market: SGTX exceeded the US Market which returned 2.4% over the past year.

Price Volatility

Is SGTX's price volatile compared to industry and market?
SGTX volatility
SGTX Average Weekly Movement127.6%
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: SGTX's share price has been volatile over the past 3 months.

Volatility Over Time: SGTX's weekly volatility has increased from 65% to 128% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201562Rogerio Coelhohttps://sigilon.com

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes.

Sigilon Therapeutics, Inc. Fundamentals Summary

How do Sigilon Therapeutics's earnings and revenue compare to its market cap?
SGTX fundamental statistics
Market capUS$56.50m
Earnings (TTM)-US$30.24m
Revenue (TTM)US$17.65m

3.2x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SGTX income statement (TTM)
RevenueUS$17.65m
Cost of RevenueUS$29.37m
Gross Profit-US$11.71m
Other ExpensesUS$18.53m
Earnings-US$30.24m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-12.03
Gross Margin-66.36%
Net Profit Margin-171.29%
Debt/Equity Ratio0%

How did SGTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.